Cost-effectiveness of Daclatasvir in Combination with Sofosbuvir for the Treatment of Subjects with Genotype 3 Chronic Hepatitis C Infection in the United States

被引：0
|
作者：
Thibault, Catherine St-Laurent [1 ]
Moorjaney, Divya [1 ]
Ganz, Michael [1 ]
Sill, Bruce E. [2 ]
Hede, Shalini [2 ]
Yuan, Yong [2 ]
Kalsekar, Anupama [2 ]
Gorsh, Boris [2 ]
机构：
[1] Evidera, Modeling & Simulat, St Laurent, PQ, Canada
[2] Bristol Myers Squibb Co, Plainsboro, NJ USA
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1461
引用
收藏
页码：923A / 923A
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States
    Thibault, Catherine Saint-Laurent
    Moorjaney, Divya
    Ganz, Michael L.
    Sill, Bruce
    Hede, Shalini
    Yuan, Yong
    Gorsh, Boris
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (07) : 692 - 702
  • [2] Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States
    Thibault, Catherine Saint-Laurent
    Moorjaney, Divya
    Ganz, Michael L.
    Sill, Bruce
    Hede, Shalini
    Yuan, Yong
    Gorsh, Boris
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (11) : 1123 - 1125
  • [3] Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada
    Moshyk, A.
    Martel, M. -J.
    Monfared, A. A. Tahami
    Goeree, R.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (02) : 181 - 192
  • [4] Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
    Phil McEwan
    Samantha Webster
    Thomas Ward
    Michael Brenner
    Anupama Kalsekar
    Yong Yuan
    Cost Effectiveness and Resource Allocation, 15
  • [5] Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection
    Sundaram, Vinay
    Kowdley, Kris V.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (01) : 13 - 20
  • [6] Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
    Sperl, Jan
    Frankova, Sona
    Kreidlova, Miluse
    Merta, Dusan
    Tothova, Monika
    Spicak, Julius
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 733 - 738
  • [7] Estimating the cost-effectiveness of daclatasvir plus sofosbuvir versus sofosbuvir plus ribavirin for patients with genotype 3 hepatitis C virus
    McEwan, Phil
    Webster, Samantha
    Ward, Thomas
    Brenner, Michael
    Kalsekar, Anupama
    Yuan, Yong
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [8] Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States
    Eckman, Mark H.
    Talal, Andrew H.
    Gordon, Stuart C.
    Schiff, Eugene
    Sherman, Kenneth E.
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (10) : 1382 - 1393
  • [9] Cost-Effectiveness of Screening for Chronic Hepatitis C Infection in the United States
    Eckman, Mark H.
    Gordon, Stuart C.
    Talal, Andrew
    Schiff, Eugene R.
    Sherman, Kenneth E.
    HEPATOLOGY, 2012, 56 : 261A - 261A
  • [10] COST-EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR FOR THE TREATMENT OF GENOTYPE 1 OR 4 CHRONIC HEPATITIS C IN SCOTLAND
    Dillon, J.
    Treharne, C.
    Howells, R.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S635 - S635
12345